



IP4 R PCT/PTO 12 JAN 2006

Attorney Docket No.: 1396-1-011PCT/US

#3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Peter Knox, et al.  
SERIAL NO.: 10/540,645 EXAMINER: Unassigned  
DATE FILED: June 24, 2005 ART UNIT: 1615  
FOR: PIPERIDINYL-THIAZOLE, CARBOXYLIC ACID  
DERIVATIVES AS ANGIOGENESIS INHIBITORS

**CERTIFICATE OF MAILING UNDER 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 9, 2006.

Karen Garipoli  
(Name of Depositor)

Karen Garipoli 1/9/06  
(Signature and Date)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.



Attorney Docket No.: 1396-1-011PCT/US

Enclosed please find copies of References **AA** through **DG** listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

DAVID A. JACKSON  
Attorney for Applicants  
Registration No. 26,742

KLAUBER & JACKSON LLC  
411 Hackensack Avenue, 4<sup>TH</sup> Floor  
Hackensack, New Jersey 07601  
201-487-5800



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office  LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT  (Use several sheets if necessary)	ATTORNEY DOCKET NO.	1396-1-011PCT/US
	SERIAL NO.	10/540,645
	APPLICANT	Peter Knox et al.
	FILING DATE	June 24, 2005
	GROUP	1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	3,966,748	6/29/76	Hofmann et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
	BA	WO 95/33050	12/7/95	PCT			
	BC	WO 99/00356	1/7/99	PCT			


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Lu, Ming, et al, Vascular endothelial growth factor gene regulation and action in diabetic retinopathy, 2002, Ophthalmol Clin N Am 15; Pgs. 69-79
CB	Weidner, N, et al, Tumor Angiogenesis and Metastasis-Correlation In Invasive Breast Carcinoma 1991, The New England Journal of Medicine, Vol 324; No. 1: Pgs. 1-8
CC	Moen, M, et al, The familial risk of endometriosis, 1993, Acta Obstet Gynecol Scand 72 Pgs 560-564
CD	Blann, A, et al, Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes, 2002, Clinical Science, 102, Pgs. 187-194
CE	Slaton, JW, et al, Expression Levels of Genes that Regulate Metastasis and Angiogenesis Correlate with Advanced Pathological Stage of Renal Cell Carcinoma, 2001, Amer Jour of Path, Vol 158, No. 2: Pgs. 735-743
CF	Thomas, EJ, et al, The aetiology and pathogenesis of endometriosis, 1992, Reproductive Med Review, 1: Pgs. 21-36
CG	Noma, H, et al, Regulation of Angiogenesis in Diabetic Retinopathy, Possible Balance Between Vascular Endothelial Growth Factor and Endostatin, 2002, Arch Ophth, Vol 120, Pgs. 1075-1080
CH	Ferrara, N, et al, Pituitary Follicular Cells Secrete A Novel Heparin-Binding Growth Factor Specific For Vascular Endothelial Cells, 1989, Biochem & Biophys Research Comm; Vol 161, pgs. 851-858

EXAMINER:

DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PCT/US 101 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY, DOCKET NO.	1396-1-011PCT/US
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	SERIAL NO.	10/540,645
	APPLICANT	Peter Knox et al.
	FILING DATE	June 24, 2005
	GROUP	1615


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CI	Creamer,D, etal, Mediation of Systemic Vascular Hyperpermeability in Severe Psoriasis by Circulating Vascular Endothelial Growth Factor, 2002, Arch Dermatology, Vol 138, Pgs. 791-796
CJ	Klagsbrun,M,etal,VEGF/VPT the angiogenesis factor found?,1993, Curr Biol, Vol 3,No 10;Pg 699-702
CK	Adams,J, etal, Vascular Endothelial Growth Factor (VEGF) in Breast Cancer:Comparison of Plasma, Serum, and Tissue VEGF and Microvessel Density and Effects of Tamoxifen <sup>1</sup> , 2000, Cancer Research 60, Pgs. 2898-2905
CL	Inoue, K, etal, The Prognostic Value of Angiogenesis Factor Expression for Predicting Recurrence and Metastasis of Bladder Cancer after Neoadjuvant Chemotherapy and Radical Cystectomy <sup>1</sup> , 2000, Clinical Cancer Research, Vol 6, Pgs. 4866-4873
CM	Borre, M, etal, Association Between Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF), VEGF-expressing Neuroendocrine-differentiated Tumor Cells, and Outcome in Prostate Cancer Patients Subjected to Watchful Waiting <sup>1</sup> , 2000,Clin Cancer Res, 6, Pgs. 1882-1890
CN	Shih, CH, etal, Vascular Endothelial Growth Factor Expression Predicts Outcome and Lymph Node Metastasis in Squamous Cell Carcinoma of the Esophagus <sup>1</sup> , 2000, Clin Cancer Res., 6; Pgs 1161-68
CO	Kaya, M etal, Vascular Endothelial Growth Factor Expression in Untreated Osteosarcoma Is Predictive of Pulmonary Metastasis and Poor Prognosis <sup>1</sup> , 2000, Clin Cancer Res., 6; Pgs. 572-577
CP	Tabone, MD, etal, Are Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Prognostic Indicators in Pediatric Patients with Malignant Solid Tumors?, 2001, Clinical Cancer Research., 6, Pgs. 538-543
CQ	Cascinu, S, etal, Expression of Vascular Endothelial Growth factor Can Predict Event-free Survival in Stage II Colon Cancer, 2000, Clinical Cancer Research, 6; Pgs. 2803-2807
CR	Aiello, LP, Vascular Endothelial Growth Factor and the Eye:Biochemical Mechanisms of Action and Implications for Novel Therapies, 1997, Ophthalmic Res., 29: Pgs. 354-362
CS	Treloar, SA, etal, Genetic influences on endometriosis in an Australian twin sample, 1999, Fertility and Sterility, Vol 71, No. 4, Pgs. 701-710
CT	Afuwape, AO, etal, The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis, 2002, Histology and Histopathology, 17: Pgs. 961-972
CU	Folkman, J, What is the Evidence That Tumors Are Angiogenesis Dependent?, 1990, Journal of the National Cancer Institute; Vol 82, No.1, 3 pages
CV	Dvorak, HF, etal, Induction of a Fibrin-Gel Investment: An Early Event in Line 10 Hepatocarcinoma Growth Mediated by Tumor-Secreted Products <sup>1</sup> , 1979, Journal of Immun, 122: Pgs. 166-174

EXAMINER:

DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1010-1015 U.S. Department of Commerce Patent and Trademark Office  LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT  (Use several sheets if necessary)	ATTORNEY, DOCKET NO.	1396-1-011PCT/US
	SERIAL NO.	10/540,645
	APPLICANT	Peter Knox et al.
	FILING DATE	June 24, 2005
	GROUP	1615

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CW	Shen, GH, etal, Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma, 2000, British Journal of cancer, 83(2); Pgs. 196-203
CX	Loncaster, JA, etal, Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix, 2000, British Journal of Cancer, 83(5): Pgs. 620-625
CY	Mineta,H, etal, Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas, 2000, British Journal of Cancer, 83(6): Pgs. 775-781
CZ	Yudoh, K, etal, Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas, 2001, British Jour of Cancer, 84(12): Pgs. 1610-1615
DA	Funatsu,H, etal, Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy, 2002, J Cataract Refract Surg; 28:Pgs. 1355-1363
DB	Abdulrauf, Saleem I, etal, Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma, 1998, J .Neurosurg 88: Pgs. 513-520
DC	Tilton, R, Diabetic Vascular Dysfunction: Links to Glucose-Induced Reductive Stress and VEGF, 2002, Microscopy Research and Technique 57: Pgs. 390-407
DD	Folkman, J., etal, Angiogenesis, 1992, The Jour of Biol Chem, Vol 267, No. 16; Pgs. 10931-10934
DE	Kennedy, S, etal, Genetics - Familial Endometriosis*, 1995, Jour of Assist Reproduct and Genetics, Vol 12, No.1, Pgs. 32-34
DE	Vaisman, N, etal, Characterization of the Receptors for Vascular Endothelial Growth Factor*, 1990, The Journal of Biological Chemistry, Vol 265, No. 32: Pgs. 19461-19466
DG	Malinak, LR, etal, Heritable aspects of endometriosis, 1980, Am. J. Obstet. Gynecol, Vol. 137, No. 3, Pgs. 332-337

EXAMINER:

DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.